NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Learn more

Workspace · Cancer algorithms · Pancreas

Pancreas

Pancreas · 67,530 new · 52,740 deaths (ACS 2026) · mortality 11.3 per 100k · 5-yr RS 13.7% (SEER)

Mortality 11.3 per 100k (SEER / ACS common-sites). Never an artboard percent.

Lifetime ≈ 1.7% (SEER Stat Facts). 113,931 people living with pancreatic cancer in 2023. Third-deadliest site by ACS 2026 deaths. No encoded screening interval.

113,931 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 71 · at death 73 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 15.7 / women 12.4 per 100k · mortality men 12.9 / women 9.9 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases rising 0.9% each year (2014–2023). Death rates stable (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval. Not a pancreas screening engine.

Highest new-case rate: Non-Hispanic Black men 18.0 per 100k. Highest death rate: Non-Hispanic Black men 15.0 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank. Not a pancreas screening engine.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
GroupInc. menInc. womenDeaths menDeaths women
Hispanic13.612.19.58.3
Non-Hispanic American Indian/Alaska Native13.413.011.010.0
Non-Hispanic Asian/Pacific Islander11.59.88.27.2
Non-Hispanic Black18.015.415.012.3
Non-Hispanic White16.312.313.410.0

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank. Not a pancreas screening engine.

USPSTF screening pointer

USPSTF 2019 D · Asymptomatic adults (not known high familial / genetic risk) · Do not screen — no biomarker engine

Cited only. No screening interval and no unpublished coefficient. USPSTF-pancreas-2019

ACS early-detection pointer

ACS 2024 · People at average risk of pancreatic cancer · ACS (2024): no major professional groups currently recommend routine screening in people who are at average risk, because no screening test has been shown to lower the risk of dying from this cancer. Complementary to the cited USPSTF 2019 D statement. Family-history genetic testing is named; it is not encoded. Not a biomarker or imaging engine.

Cited ACS statement only. Not a screening engine. ACS-pancreas-detect

Surveillance pointer

ACS-pancreas-follow 2024 · cited only · ACS living-as-a-survivor page names typical post-treatment follow-up visits that may include CT scans and blood tests. Those months are not encoded. Not a recurrence-coefficient engine.

Named public source only. Not a personal follow-up calendar. ACS-pancreas-follow

Surveillance pointer

ACS-pancreas-second 2024 · cited only · ACS second-cancers page names regular visits after pancreatic-cancer treatment and says most experts do not recommend additional testing to look for second cancers unless you have symptoms or an inherited genetic syndrome. Inherited-syndrome calendars are named, not encoded. Complementary to the ACS living-as pointer. Not a second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-pancreas-second

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names bowel blockage from adhesions after abdomen treatment, plus fertility effects after chemo or radiation to the pelvis, belly, or spine. Those names are not encoded. Complementary to the living-as pointer. Not an inherited-syndrome or second-primary engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Those plans are not encoded. Complementary to the GI printout. Not an inherited-syndrome, Lynch, or CA-125 engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

ACS-pancreas-follow 2024 · empty on purpose · ACS living-as-a-survivor page names treatment side effects. Those late effects are not encoded. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-pancreas-follow

Toxicity pointer

ACS-pancreas-second 2024 · empty on purpose · ACS second-cancers page names later cancers after pancreatic-cancer treatment. Those second-cancer risks are not encoded. Inherited syndromes are named, not encoded. Complementary to the ACS living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-pancreas-second

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later bowel blockage from adhesions and fertility effects after abdomen treatment. Those late effects are not encoded. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after abdomen treatment. Those named tests are not encoded. Complementary to the GI printout. Not an inherited-syndrome or CA-125 engine. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

Late toxicity printout — GI

Acute: ACS names nausea, heartburn, cramps, diarrhea or constipation, bowel urgency, and rectal or anal skin irritation. Late: radiation proctitis, bowel incontinence, ostomy or chronic bowel change, neuropathy, adhesions, urinary trouble after pelvis RT, fertility effects, sexuality changes, lasting fatigue, cavities after chemo, and cognitive change after chemo. Monitor: on-treatment diarrhea; proctitis after 3 to 6 months; lasting fatigue or sleep problems; sexuality or body-image change; fertility after pelvis, belly, or spine treatment; cavity risk after chemo; memory, thinking, or focus change after chemo; a treatment summary and second-cancer watching. Those names are not encoded. Official esophagus share-of-new-cases figures are not restated. Not a Lynch or endoscopy engine.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

  • Bowel obstruction from adhesions
  • Urinary retention or incontinence after pelvis RT
  • Fertility after pelvis, belly, or spine RT
  • Sexuality after cancer treatment
  • Cancer-related fatigue that lasts
  • Joint or muscle pain after some treatments
  • Mental health and distress after treatment
  • Cavities and tooth loss after chemo
  • Cognitive impairment after brain RT or chemo

Named conditions to monitor

  • Diarrhea that starts during abdomen RT
  • Radiation proctitis after 3 to 6 months
  • Second-cancer testing
  • Bowel blockage or bladder-emptying trouble
  • Cancer-related fatigue or sleep problems that last
  • Joint or muscle pain after chemo, steroids, or hormone therapy
  • Anxiety, depression, or fear of recurrence after treatment
  • Sexuality or body-image change after treatment
  • Fertility after pelvis, belly, or spine treatment
  • Cavity risk after chemo
  • New or worsening memory, thinking, or focus
  • Second-cancer awareness after radiation or chemo
  • Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS abdomen / pelvis / CRC names only. Complementary ACS long-term page is named, not encoded. Official esophagus share-of-new-cases figures are not restated. No invented trial percent.

Open GI printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-pancreas · stub · none · v2-stub-pancreas

SEER 5-year relative survival by stage (cited stub)

Localized 43.6% · Regional 17.0% · Distant 3.4% · All 13.7%

Most cases present distant. Not a pancreas screening engine.

Percent of cases by stage (SEER Stat Facts)

Localized 15% · Regional 28% · Distant 51% · Unknown 5%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Not a pancreas screening engine.

  • lifetime

    Pancreas birth-to-death

    ≈ 1.7%

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    USPSTF 2019 D — do not screen average-risk pancreas

    Cited USPSTF 2019 D and ACS 2024 statements. No biomarker or imaging engine.

    not encoded

  • surveillance

    ACS follow-up cited — pancreas months not encoded

    Cited ACS living-as-a-survivor page only. No invented recurrence coefficient.

    not encoded

  • toxicity

    ACS late effects cited — pancreas months not encoded

    Empty on purpose. Named ACS side effects are not encoded.

    not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    USPSTF 2019 D — do not screen average-risk pancreas

    Cited USPSTF 2019 D and ACS 2024 statements. No biomarker or imaging engine.

    not encoded

  • surveillance

    ACS follow-up cited — pancreas months not encoded

    Cited ACS living-as-a-survivor page only. No invented recurrence coefficient.

    not encoded

  • toxicity

    ACS late effects cited — pancreas months not encoded

    Empty on purpose. Named ACS side effects are not encoded.

    not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    USPSTF 2019 D — do not screen average-risk pancreas

    Cited USPSTF 2019 D and ACS 2024 statements. No biomarker or imaging engine.

    not encoded

  • surveillance

    ACS follow-up cited — pancreas months not encoded

    Cited ACS living-as-a-survivor page only. No invented recurrence coefficient.

    not encoded

  • toxicity

    ACS late effects cited — pancreas months not encoded

    Empty on purpose. Named ACS side effects are not encoded.

    not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    USPSTF 2019 D — do not screen average-risk pancreas

    Cited USPSTF 2019 D and ACS 2024 statements. No biomarker or imaging engine.

    not encoded

  • surveillance

    ACS follow-up cited — pancreas months not encoded

    Cited ACS living-as-a-survivor page only. No invented recurrence coefficient.

    not encoded

  • toxicity

    ACS late effects cited — pancreas months not encoded

    Empty on purpose. Named ACS side effects are not encoded.

    not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →